AU · rank #18 · 2026-09-08
CORT
NASDAQ · $11.94B (USD)
The exact numbers the algorithm saw.
| Composite score Z-score blend of all factors below. | 0.682 |
|---|---|
| EPS revisions (30d) Change in consensus EPS estimate over the past 30 days ($/share). | +$1.20 |
| Net revisions (30d) Number of analysts revising upward minus downward. | 2 |
| Insider signal (90d) $0 across 0 unique buyers. | -0.186 |
| Analyst upside Consensus target $141.00 | +26.3% |
| Momentum acceleration 3-month minus 12-month momentum. | +28.71% |
| Analyst rating 5 = Strong Buy, 1 = Strong Sell. | 4.50 |
| Gross margin TTM | +98.3% |
| 52w high | $126.38 |
| Market cap (USD) | $11.94B |
The AI research card
Independent qualitative review of each pick before the order is placed. On the rare day the research service is unavailable, the paper book trades on the quant ranking alone and no card appears here.
Summary
Corcept Therapeutics is a profitable specialty biopharma generating over $200M per quarter from Korlym and its authorized generic in Cushing's syndrome, now adding a second commercial product in Lifyorli.
Rationale
The analyst_upside_pct of 26% is reinforced by a 535% earnings surprise, 32% revenue growth, raised full-year guidance, and 100% revision agreement among analysts lifting EPS estimates over 30/60/90-day windows — the momentum and estimate-revision signals are grounded in real fundamental acceleration, not sentiment alone.
Material risks
- 1Revenue concentration in a single indication (Korlym/authorized generic ~$209M of $256M quarterly revenue) means any competitive entry or reimbursement disruption would directly collapse the earnings base underpinning the raised guidance and analyst targets.
- 2With only 4 analysts covering the name, a target dispersion of 81.6%, zero insider buying in 90 days, and the stock already up ~20% post-earnings to a 52-week high, the 26% analyst upside may already be substantially priced in with thin institutional sponsorship to sustain the move.
AI verdict council
Each pick is reviewed independently by 3 models before any order. 3 of 3 voted to proceed.